Skip to main content

Advertisement

SpringerLink
Log in

Pediatric Antiphospholipid Syndrome

  • Antiphospholipid Syndrome (D Erkan, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by vascular thromboses associated with persistently positive antiphospholipid antibodies. There is currently a paucity of data (incidence, prevalence, thrombosis risk, and effective treatment) in pediatric APS. The purpose of this report is to review the current literature on APS in children and neonates, identify the gaps in current knowledge, and suggest avenues for studies to fill those gaps.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

    CAS  PubMed  Google Scholar 

  2. Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001;40(5):565–73.

    CAS  Google Scholar 

  3. Berkun Y, Simchen M, Strauss T, et al. Antiphospholipid antibodies in neonates with stroke–a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986–93.

    CAS  PubMed  Google Scholar 

  4. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9(3):212–8.

    CAS  PubMed  Google Scholar 

  5. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46(2):545–52.

    CAS  PubMed  Google Scholar 

  6. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus. 1998;7 Suppl 2:S52–4.

    CAS  PubMed  Google Scholar 

  7. Gharavi AE, Vega-Ostertag M, Espinola RG, et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus. 2004;13(1):17–23.

    CAS  PubMed  Google Scholar 

  8. Wenzel C, Stoiser B, Locker G, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763–70.

    CAS  PubMed  Google Scholar 

  9. Cruz-Tapias P, Blank M, Anaya JM, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.

    CAS  PubMed  Google Scholar 

  10. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711–4.

    CAS  PubMed  Google Scholar 

  11. Andreoli L, Nalli C, Motta M, et al. Anti-B2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis. 2011;70(2):380–3.

    CAS  PubMed  Google Scholar 

  12. Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013;22(7):702–11.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Guerin J, Casey E, Feighery C, et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31(2):109–16.

    CAS  PubMed  Google Scholar 

  14. Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-Beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18(11):1011–4.

    CAS  PubMed  Google Scholar 

  15. Samarkos M, Davies K, Gordon C, et al. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25(2):199–204.

    CAS  PubMed  Google Scholar 

  16. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.

    CAS  PubMed  Google Scholar 

  17. Erkan D, Lockshin M. High risk antiphospholipid antibody profile: matter of the number or titer of tests? E-letter to the editor (re: Incidence of first thrombembolic event in asymptomatic carries of high-risk aPL profile: a multicenter prospective study, Pengo et al. Blood 2011;17:4714). Published online on 24 January 2012, available at: http://bloodjournal.hematologylibrary.org/letters.

  18. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.

    CAS  PubMed  Google Scholar 

  19. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5(5):925–30.

    CAS  PubMed  Google Scholar 

  20. Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94.

    PubMed Central  CAS  PubMed  Google Scholar 

  21. Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatol Med. 2006;11(3):198–206.

    Google Scholar 

  22. Male C, Lechner K, Eichinger S, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134(2):199–205.

    CAS  PubMed  Google Scholar 

  23. Flanders MM, Crist RA, Roberts WL, et al. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51(9):1738–42.

    CAS  PubMed  Google Scholar 

  24. Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7. Most comprehensive descriptive characteristics of pediatric APS from an international registry.

    PubMed  Google Scholar 

  25. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci. 2005;1051:465–86.

    CAS  PubMed  Google Scholar 

  26. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74(1):415–25.

    CAS  PubMed  Google Scholar 

  27. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–7.

    CAS  PubMed  Google Scholar 

  28. Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein 1 antibodies in infants born to mother with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol. 2006;23(4):247–51.

    PubMed  Google Scholar 

  29. Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.

    PubMed Central  PubMed  Google Scholar 

  31. Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford). 2001;40(9):1026–32.

    CAS  Google Scholar 

  32. Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclases. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40(11):1998–2006.

    CAS  PubMed  Google Scholar 

  33. Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus. 2007;16(8):634–41.

    Google Scholar 

  34. Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res. 2014;2014:672603.

    PubMed Central  PubMed  Google Scholar 

  35. Boffa MC, Aurousseau MH, Lachassinne E, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13(9):713–7.

    CAS  PubMed  Google Scholar 

  36. Boffa MC, Lachassinne E, Boinot C, et al. European registry of babies born to mothers with antiphospholipid syndrome: a result update. Lupus. 2009;18(10):900–4.

    PubMed  Google Scholar 

  37. Mekinian A, Carbillon L, Nicaise-Roland P, et al. Mothers’ antiphospholipid antibodies during pregnancy and the relation to offspring outcome. Clin Exp Rheumatol. 2014;32(3):446.

    CAS  PubMed  Google Scholar 

  38. Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217–22. A prospective study aiming to describe the long-term outcomes of children born to mothers with antiphospholipid syndrome.

    PubMed Central  PubMed  Google Scholar 

  39. Nalli C, Iodice A, Andreoli L, et al. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus. 2014;23(6):507–17.

    CAS  PubMed  Google Scholar 

  40. Ross G, Sammaritano L, Nass R, et al. Affects of mother’s autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157(4):397–402.

    PubMed  Google Scholar 

  41. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med. 1999;27(3):183–7.

    CAS  PubMed  Google Scholar 

  42. Nacinovich R, Galli J, Bomba M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum. 2008;59(3):345–51.

    CAS  PubMed  Google Scholar 

  43. Abisror N, Mekinian A, Lachassinne E, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;43(3):348–51.

    CAS  PubMed  Google Scholar 

  44. Gordon O, Almagor Y, Fridler D, et al. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 2014;44(2):241–5. A recent review of de novo neonatal APS.

    PubMed  Google Scholar 

  45. Hansen K, Kong D, Moore K, et al. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001;28(9):2018–24.

    CAS  PubMed  Google Scholar 

  46. Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothromboitc risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30(11):2385–91.

    PubMed Central  CAS  PubMed  Google Scholar 

  47. Rosendaal F, Siscovick D, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89(8):2817–21.

    CAS  PubMed  Google Scholar 

  48. Giron-Gonzalez J, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560–7.

    Google Scholar 

  49. Kaul M, Erkan D, Sammaritano L, et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927–30.

    PubMed Central  PubMed  Google Scholar 

  50. Tolbert J, Carpenter SL. Common acquired causes of thrombosis in children. Curr Probl Pediatr Adolesc Health Care. 2013;43(7):169–77.

    PubMed  Google Scholar 

  51. Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9.

    CAS  PubMed  Google Scholar 

  52. Albisetti M, Moeller A, Waldvogel K, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol. 2007;117(3):149–55.

    PubMed  Google Scholar 

  53. Revel-Vilk S, Chan A, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1(5):915–21.

    CAS  PubMed  Google Scholar 

  54. Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am. 2013;60(6):1443–62.

    PubMed  Google Scholar 

  55. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011;37(7):802–9. A meta-analysis describing the impact of antiphospholipid antibodies on the risk of thrombotic events in children.

    CAS  Google Scholar 

  56. Manco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol. 1995;48(4):240–3.

    CAS  PubMed  Google Scholar 

  57. Tavil B, Ozyurek E, Gumruk F, et al. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347–52.

    CAS  PubMed  Google Scholar 

  58. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19(4):406–11.

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Lampropoulos CE, Koutroumanidis M, Reynolds PP, et al. Electroencephalography in the assessment of neuropsychiatric manifestation in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.

    PubMed  Google Scholar 

  60. Biernacka-Zielinska M, Lipinska J, Szymanska-Kaluza J, et al. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report. J Med Case Rep. 2013;7:221.

    PubMed Central  PubMed  Google Scholar 

  61. Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23:1449–51.

    CAS  PubMed  Google Scholar 

  62. Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):206–13.

    PubMed  Google Scholar 

  63. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.

    CAS  PubMed  Google Scholar 

  64. von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002;47(4):414–20.

    Google Scholar 

  65. Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia. 2002;43(1):52–9.

    CAS  PubMed  Google Scholar 

  66. Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit. 2009;15(4):CR164–9.

    CAS  PubMed  Google Scholar 

  67. Avčin T, Markelj G, Nikšič V, et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia. 2004;24(10):831–7.

    Google Scholar 

  68. Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes’) syndrome: changing the face of neurology. Eur J Intern Med. 2004;15(3):147–50.

    CAS  PubMed  Google Scholar 

  69. Careaga M, Hansen RL, Hertz-Piccotto I, et al. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.

    PubMed Central  PubMed  Google Scholar 

  70. Zamora-Ustaran A, Escarcega-Alarcón RO, Garcia-Carrasco M, et al. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J. 2012;14(5):286–9.

    PubMed  Google Scholar 

  71. Mazodier K, Arnaud L, Mathian A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):251–60.

    Google Scholar 

  72. Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850–5.

    CAS  Google Scholar 

  73. Garcia-Carrasco M, Galarza C, Gómez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus. 2007;16(5):366–73.

    CAS  PubMed  Google Scholar 

  74. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.

    PubMed  Google Scholar 

  75. Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003;12(6):449–53.

    CAS  PubMed  Google Scholar 

  76. Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.

    Google Scholar 

  77. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16(8):627–33.

    CAS  PubMed  Google Scholar 

  78. Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997;6(6):556–7.

    CAS  PubMed  Google Scholar 

  79. Caporali R, Ravelli A, Ramenghi B, et al. Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. Arch Dis Child. 1992;67(11):1384–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  80. Abend NS, Licht DJ, Spencer CH. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatr Neurol. 2007;36(5):345–7.

    PubMed  Google Scholar 

  81. Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated henoch-Schonlein purpura. Arch Dis Child. 2002;86(2):132–3.

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Meglic A, Grosek S, Benedik-Dolnicar M, et al. Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus. 2008;17(9):842–5.

    CAS  Google Scholar 

  83. Sherer Y, Livneh A, Levy Y, et al. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome: a novel overlap syndrome. Lupus. 2000;9(1):42–6.

    CAS  Google Scholar 

  84. Fung VS, Yiannikas C, Sue CM, et al. Is Sydenham’s chorea an antiphospholipid syndrome? J Clin Neurosci. 1998;5(1):115–8.

    CAS  PubMed  Google Scholar 

  85. Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as a presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics. 1999;30(2):96–8.

    CAS  PubMed  Google Scholar 

  86. Caporali R, Ravelli A, De Gennaro F, et al. Prevalence of anticardiolipin antibodies in juvenile arthritis. Ann Rheum Dis. 1991;50(9):599–601.

    PubMed Central  CAS  PubMed  Google Scholar 

  87. Southwood TR, Roberts-Thomson PJ, Ahern MJ, et al. Autoantibodies in patients with juvenile chronic arthritis and their immediate family relatives. Ann Rheum Dis. 1990;49(12):968–72.

    PubMed Central  CAS  Google Scholar 

  88. Gedalia A, Molina IF, Garcia CO, et al. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus. 1998;7(8):551–3.

    CAS  PubMed  Google Scholar 

  89. Rožiĝ M, Trampuš-Bakija A, Rener-Primec Z, et al. Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies. Arthritis Rheum. 2008;58:S711–2.

    Google Scholar 

  90. Avcin T, Cimaz R, Meroni PL. Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in paediatric population? Lupus. 2001;10(12):897–8.

    CAS  PubMed  Google Scholar 

  91. Cabiedes J, Trejo-Hernandez J, Loredo-Abdala A, et al. Anti-cardiolipin, anticardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population. Arch Med Res. 2002;33(2):175–9.

    CAS  PubMed  Google Scholar 

  92. Vaarala O, Palosuo T, Kleemola M, et al. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41(1):8–15.

    CAS  PubMed  Google Scholar 

  93. Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005;210(10):799–805.

    CAS  PubMed  Google Scholar 

  94. Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005;142(2):377–80.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Toplak N, Kveder T, Trampuš-Bakija A, et al. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. 2008;8(2):134–8.

    CAS  PubMed  Google Scholar 

  96. Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal. 2000;14(3):87–90.

    CAS  PubMed  Google Scholar 

  97. Siemens HJ, Gutsche S, Brückner S, et al. Antiphospholipid antibodies in children without and in adults with and without thrombophilia. Thromb Res. 2000;98(4):241–7.

    CAS  PubMed  Google Scholar 

  98. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus. 2002;11(1):4–10.

    CAS  PubMed  Google Scholar 

  99. Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):553–73.

    PubMed  Google Scholar 

  100. Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523.

    PubMed  Google Scholar 

  101. Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome. J Pediatr. 1997;130(6):998–1000.

    CAS  PubMed  Google Scholar 

  102. Lee MT, Nardi MA, Hadzi-Nesic J, et al. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1½-year-old girl: report of a case and review of the literature. Am J Hematol. 1996;51(4):307–14.

    CAS  PubMed  Google Scholar 

  103. Yacobovich JR, Uziel Y, Friedman Z, et al. Diffuse muscular haemorrhage as presenting sign of juvenile systemic lupus erythematosus and lupus anticoagulant hypoprothrombinaemia syndrome. Rheumatology (Oxford). 2001;40(5):585–7.

    CAS  Google Scholar 

  104. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8.

    CAS  PubMed  Google Scholar 

  105. Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol. 2004;26(5):327–30.

    PubMed  Google Scholar 

  106. Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322–32.

    PubMed  Google Scholar 

  107. Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008;34(3):282–5.

    CAS  Google Scholar 

  108. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4.

    CAS  PubMed  Google Scholar 

  109. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64(8):1205–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  110. Manco-Johnson M, Wang M, Goldenberg N, et al. Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J Pediatr. 2012;161(4):682–8.

    Google Scholar 

  111. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):74–9.

    PubMed  Google Scholar 

  112. Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnosis a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5(6):305–14. A review article summarizing the diagnostic challenges and recently updated diagnostic algorithms for CAPS.

    PubMed Central  CAS  PubMed  Google Scholar 

  113. Berman H, Rodríguez-Pintó I, Cervera R, et al. Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014;13(2):157–62. A descriptive analysis of pediatric patients from the CAPS registry.

    PubMed  Google Scholar 

  114. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12(7):499–503.

    CAS  PubMed  Google Scholar 

  115. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.

    CAS  PubMed  Google Scholar 

  116. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.

    CAS  PubMed  Google Scholar 

  117. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467–73.

    CAS  PubMed  Google Scholar 

  118. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192–200.

    CAS  PubMed  Google Scholar 

  119. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8.

    CAS  PubMed  Google Scholar 

  120. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509.

    CAS  PubMed  Google Scholar 

  121. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6(2):98–103.

    CAS  PubMed  Google Scholar 

  122. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):70–6.

    PubMed  Google Scholar 

  123. Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer. 2009;52(4):536–8.

    PubMed  Google Scholar 

  124. Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics. 2010;125(6):e1523–8.

    PubMed  Google Scholar 

  125. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12(11):1085–90. A descriptive analysis of the use of rituximab in pediatric CAPS.

    CAS  PubMed  Google Scholar 

  126. Erkan D, Aguiar CL, Andrade D, et al. 14th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. A comprehensive review of the various treatments being used and studied for APS.

    CAS  PubMed  Google Scholar 

  127. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185–90.

    CAS  PubMed  Google Scholar 

  128. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.

    CAS  PubMed  Google Scholar 

  129. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84. This is a prospective cohort study within the Warfarin versus Aspirin Recurrent Stroke Study (WARSS) [126] that specified in advance APS-related data and sample collection parameters and could be a model for future studies.

    CAS  PubMed  Google Scholar 

  130. Liu X-W, Pierangeli SS, Barker J, et al. RBC adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin. Ann N Y Acad Sci. 1998;850:391–3.

    CAS  PubMed  Google Scholar 

  131. Westerman M, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–62.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge the suggestions and recommendations of Patricia Massicotte, M.D. of the University of Alberta.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Cassyanne L. Aguiar, Arzu Soybilgic, Tadej Avcin, and Barry L. Myones declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Pediatric Rheumatology, Cohen Children’s Medical Center—North Shore Long Island Jewish Medical Center, The Hofstra North Shore-LIJ School of Medicine, 1991 Marcus Avenue, Suite M100, Lake Success, NY, 11040, USA

    Cassyanne L. Aguiar

  2. Pediatric Rheumatology, Children’s Hospital of University of Illinois, 840 S. Wood St, 1206 CSB, Chicago, IL, 60612, USA

    Arzu Soybilgic

  3. Department of Allergology, Rheumatology and Clinical Immunology, Children’s Hospital, University Medical Center Ljubljana, Bohoriceva 20, 1525, Ljubljana, Slovenia

    Tadej Avcin

  4. Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Bohoriceva 20, 1525, Ljubljana, Slovenia

    Tadej Avcin

  5. Pediatric Rheumatology, 2119 Plantation Bend Drive, Sugar Land, TX, 77478, USA

    Barry L. Myones

Authors
  1. Cassyanne L. Aguiar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arzu Soybilgic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadej Avcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barry L. Myones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cassyanne L. Aguiar.

Additional information

This article is part of the Topical Collection on Antiphospholipid Syndrome

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aguiar, C.L., Soybilgic, A., Avcin, T. et al. Pediatric Antiphospholipid Syndrome. Curr Rheumatol Rep 17, 27 (2015). https://doi.org/10.1007/s11926-015-0504-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0504-5

Keywords

Search

Navigation